Annual Review 2025: Reflecting on a Year of Progress and Purpose

BlueRock Therapeutics has published 18-month data from its Phase I clinical trial for an investigational cell therapy to treat Parkinson’s disease in Nature, indicating no serious adverse events related to the therapy and showing sustained neuron cell engraftment.

Andes published a peer-reviewed scientific paper with leading researchers from Yale University, The University of Texas, University of Colorado Boulder, Universidad Adolfo Ibáñez and Leibniz Universität Hannover. This work outlines a first-of-its-kind CDR strategy leveraging beneficial microbes that farmers can implement on agricultural fields across the globe. It examines the role of microbial processes in enhancing carbon dioxide removal through soil-based strategies, including the microbial acceleration of native silicate weathering, the very mechanism Andes is deploying today across the U.S. Midwest through the Andes Carbon Program.

BlueRock Therapeutics has advanced its investigational cell therapy for Parkinson’s disease into a registrational Phase III clinical trial. This marks the first Phase III trial of an allogeneic, pluripotent stem-cell–derived therapy for PD.

ChrysaLabs has become the first direct-contact proximal-sensing soil-carbon technology to be successfully validated by a third-party auditor for use under Verra’s VM0042 methodology. The validation, performed by Bureau Veritas North America, confirms that ChrysaLabs’ method meets rigorous international standards for measuring soil organic carbon (SOC), enabling lower-cost, scalable, and Verra-compliant carbon data for carboncredit projects.

BlueRock Therapeutics has received Fast Track designation from the FDA for its novel cell therapy treatment of primary photoreceptor diseases that cause irreversible vision loss. This designation is intended to accelerate the development and review of the drug as the company aims to restore patients' vision by replacing degenerated cells in the eye.

Grão Direto has introduced the FOB Santos Soybean Index - the first Brazilian grain price benchmark certified under IOSCO standards, with assurance by KPMG. The certification follows the same governance and audit rules used for indexes by central banks and stock exchanges, giving international credibility to Brazil’s physical soybean market. Unlike traditional pricing models based on trader surveys, the index uses real transaction data from Grão Direto’s platform, capturing daily export prices from Santos, the country’s main port.

BlueRock Therapeutics has reported positive 36-month results from its Phase I trial for an investigational cell therapy treating Parkinson’s disease, showing a favorable safety profile and stable motor outcomes compared to 24 months. The data indicates encouraging trends in secondary clinical efficacy endpoints, potentially being a meaningful therapeutic option for Parkinson’s disease patients.

EarthOptics has launched its first scalable mid-infrared (MIR) carbon testing solution, significantly reducing costs while providing registryquality soil data essential for carbon markets and sustainability initiatives. This innovation slashes the cost of traditional carbon testing while delivering fast, reliable results that meet the high-integrity data needs of carbon markets, sustainability initiatives, and Scope 3 reporting.

BlueRock Therapeutics has begun the pivotal Phase III trial with its investigational cell therapy for treating Parkinson’s disease, with the first patient receiving treatment. This trial will assess the therapy's efficacy and safety in approximately 102 participants. Depending upon the outcome, the results from this trial are intended to be part of a data package to support regulatory submissions for marketing authorization.

EarthOptics has launched its new subscription-based Total Farm program for the 2025 crop year, the company’s first major product release since merging with Pattern Ag. The platform integrates GroundOwl™ sensor data, soil DNA testing, yield data, and satellite imagery to deliver full-field soil fertility insights and crop-planning recommendations aimed at boosting yields and reducing input costs. Farmers and agronomic advisors receive high-resolution nutrient maps, biological risk assessments, and variable-rate prescriptions, with the all-inclusive service priced at a flat $4 per acre.

BlueRock Therapeutics has initiated a Phase 1/2a clinical trial for its iPSC-derived cell therapy targeting primary photoreceptor diseases, marking the first therapy of its kind and aiming to restore vision in people with inherited retinal disorders.

EarthOptics has surpassed more than five million acres of farmland and rangeland mapped, strengthening its position as the leading global platform for below-ground soil data. This rapid expansion is transforming both agronomy and sustainability measurement, while building the largest soil metagenomic dataset ever assembled, unlocking new insights into soil biology, chemistry, and physical structure across the U.S. and beyond.

eGenesis has announced the successful transplantation of a genetically engineered porcine kidney into a second patient, Tim Andrews, who had been on dialysis for over two years due to end-stage kidney disease. The transplant demonstrates the potential of genetically modified organs to improve compatibility and function in human recipients, offering hope to many suffering from kidney failure.

Oerth Bio has published a pioneering study in Nature Communications Biology demonstrating the use of PROTAC (Proteolysis-Targeting Chimera) technology for agricultural applications, showcasing its ability to precisely degrade target proteins in insects. Oerth Bio's work demonstrates how cutting-edge biotechnology platforms can be reimagined to solve some of agriculture's most urgent challenges, validating targeted protein degradation as a scalable solution for enhancing crop resilience and sustainability.

eGenesis has received FDA clearance for its Investigational New Drug application, a genetically engineered porcine kidney, with plans to conduct a clinical trial assessing its safety and efficacy in patients with end-stage kidney disease. Notably, the first patient in an ongoing study has surpassed seven months of kidney function post-transplant, and a second successful transplant has been completed, highlighting the potential of xenotransplantation to address the critical organ shortage.

Portfolio company Numerion Labs, formerly known as Atomwise, published new AI research introducing a protocol called APEX (Approximate-but-Exhaustive Search) together with NVIDIA. APEX enables scientists to virtually screen billions of compounds in seconds using a single GPU, a task that previously took months, dramatically speeding up early-stage drug discovery by making it possible to explore vastly larger chemical libraries in real time.

eGenesis and OrganOx announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure. The FDA has approved clinical studies of genetically modified pig organ transplants for patients with kidney failure - a groundbreaking advancement that could revolutionize the future of organ transplantation.

Bloom Science's Phase I trial of BL-001, an oral therapy designed to replicate the ketogenic diet, demonstrated statistically significant weight loss in overweight individuals, with participants maintaining these results two weeks after treatment. The promising data, including dose-dependent metabolic changes and minimal adverse effects, supports advancing to Phase II trials for obesity and Dravet syndrome.

Huma Therapeutics has received a Class II Medical Device License from Health Canada for its Huma Cloud Platform, enabling broader patient coverage and advancing digital health innovation across Canada. This approval allows the platform to integrate AI for enhanced patient monitoring and clinical decision support, improving care delivery for various conditions while ensuring compliance with high regulatory standards.

Sudo Biosciences reported positive Phase 1 results for SUDO-550, an oral TYK2 inhibitor designed to reach the central nervous system. The therapy showed good safety and tolerability, along with a pharmacokinetic profile that supports once-daily dosing. A Phase 2 clinical trial in multiple sclerosis is planned to start in early 2026.

Nuvig Therapeutics announced that the first patient has been dosed in its Phase 2 clinical trial evaluating NVG 2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The Phase 2 study, called INVGOR, is a multicenter, global trial evaluating the safety, tolerability, and potential clinical benefit of NVG-2089 in up to 60 participants with CIDP at 40 sites globally.

ReCode Therapeutics’ RNA therapy for the treatment of cystic fibrosis (CF), has received U.S. FDA Orphan Drug Designation. CF is a progressive genetic disease characterized by persistent lung infections and respiratory failure caused by mutations in the CFTR gene. While current treatments have improved outcomes for many, a subset of patients remains underserved.

ReCode Therapeutics announced that the FDA has cleared the start of Part 3 of its Phase 2 clinical trial evaluating RCT2100, an investigational inhaled CFTR mRNA therapy, in combination with ivacaftor, a medication used to treat cystic fibrosis (CF). The trial, now enrolling in the U.S. with plans to expand to the U.K. and EU in early 2026, aims to assess the safety, tolerability, and efficacy of this combination therapy over six weeks.

The U.S. Food and Drug Administration has awarded Cellino an Advanced Manufacturing Technology (AMT) designation for its optical biomanufacturing process used to generate induced pluripotent stem cells (iPSCs). Under the designation, therapies produced with Cellino’s automated platform will receive prioritized regulatory attention and the option for rolling data submissions, potentially shortening time to market.

Mozart Therapeutics announced that its first-in-class drug MTX-101 completed a Phase 1a study in healthy adults with good safety and tolerability, and showed selective activation of regulatory CD8 T cells (CD8 Tregs). The company has now started enrolling patients with autoimmune diseases, including type 1 diabetes and celiac disease, into Phase 1b.

CORXEL has enrolled the first patient in its global registrational trial ORION testing JX10 for acute ischemic stroke. ORION will evaluate whether its novel drug JX10, with both clot-dissolving and anti-inflammatory properties, can improve neurological recovery in stroke patients treated up to 24 hours after symptom onset, potentially expanding the narrow time window of current therapies.

CORXEL has enrolled the first patient in its U.S. Phase 2 trial of CX11, an investigational oral GLP-1 receptor agonist for obesity and overweight. The U.S. Phase 2 trial is aiming to enroll 250 patients and is designed to assess the efficacy and safety profile. Patients will receive doses of CX11once-daily over 36 weeks and will be further monitored over a 2-week observation period. Topline data from this trial is expected to be released in the first half of 2026.

In a Phase 2 trial in China among 250 overweight and obese adults, CX11 led to an average body-weight reduction of up to ~9.7% after 16 weeks; far greater than the ~1.6% weight loss seen with placebo. More than half (55%–90%) of participants who received CX11 achieved at least a 5% weight loss, versus only 13% in the placebo group.